BCMA-CD19 CAR T cell therapy (Hunan Siweikang Pharma)

BCMA-CD19 CAR T 细胞(湖南思为康医药有限公司)

Report date: 2024/02/05 15:01:03

Base Information

Drug NameBCMA-CD19 CAR T cell therapy (Hunan Siweikang Pharma)
Drug Alias Name靶向BCMA-CD19的安全型嵌合抗原受体T细胞注射液SWK001SWK-001
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsB-cell maturation protein modulators
TargetsB-lymphocyte antigen CD19B-cell maturation protein
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHunan Siweikang Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHunan Siweikang Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A